المؤلفون: Zhang Zhang, Sihua Zhu, Qian Li, Sanfang Tu, Ke Ding, Liang Jiang, Zhengchao Tu, Yuting Wang, Xiaoyun Lu

المصدر: Acta Pharmaceutica Sinica B, Vol 11, Iss 5, Pp 1315-1328 (2021)
Acta Pharmaceutica Sinica. B

مصطلحات موضوعية: Drug resistance, RM1-950, medicine.disease_cause, LSCs, leukemic stem cells, T315i mutation, IC50, cellular inhibition, T315I mutation, 03 medical and health sciences, PROTAC, Degradation, 0302 clinical medicine, CML, chronic myeloid leukemia, hemic and lymphatic diseases, T315I, threonine 315 to isoleucine 315, medicine, General Pharmacology, Toxicology and Pharmaceutics, Threonine, CRBN, cereblon, IC50, CML, 030304 developmental biology, 0303 health sciences, Mutation, TGI, tumor growth inhibition, Chemistry, NMPA, National Medical Products Administration, Myeloid leukemia, PROTAC, proteolysis-targeting chimeric, Pomalidomide, ALL, acute lymphoblastic leukemia, VHL, von Hippel-Lindau, 030220 oncology & carcinogenesis, DR, degradation rate, Cancer research, Original Article, Ph+, Philadelphia chromosome, Clinical resistance, Therapeutics. Pharmacology, Isoleucine, Co-IP, co-immunoprecipitation, cIAP1, cellular inhibitor of apoptosis protein 1, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46d7e646ae40d932bccd80bff158248
http://www.sciencedirect.com/science/article/pii/S2211383520307991